A Novel Oncogenic RET Fusion Variant in Non–Small Cell Lung Cancer: RELCH-RET
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference4 articles.
1. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer;Farago;Transl Lung Cancer Res,2017
2. Clinical and translational implications of RET rearrangements in non-small cell lung cancer;Ferrara;J Thorac Oncol,2018
3. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial;Drilon;Lancet Oncol,2016
4. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial;Lee;Ann Oncol,2017
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The landscape of actionable genomic alterations in lung adenocarcinomas in India;Frontiers in Genetics;2023-12-13
2. A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET;Journal of Thoracic Oncology;2021-10
3. Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020;JTO Clinical and Research Reports;2020-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3